Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Use of abciximab: comparative economic data.
Mark
D B
DB
Duke Clinical Research Institute, Durham, NC, USA.
Simons
T A
TA
D000077284:Abciximab; D015906:Angioplasty, Balloon, Coronary / Q000191:economics; D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000191:economics* / Q000628:therapy; D002986:Clinical Trials as Topic; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D017850:Economics, Pharmaceutical; D017721:Hospital Costs; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000191:economics* / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000191:economics* / Q000627:therapeutic use; D014481:United States
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D000077284:Abciximab